Effect of 6-week washout period on intraocular pressure following chronic prostaglandin analogue treatment: a randomized controlled trial

Lim, Carter W.; Diaconita, Vlad; Liu, Eddie; Ault, Nicholas; Lizotte, Daniel J.; Nguyen, Mary; Hutnik, Cindy

doi:10.1016/j.jcjo.2019.08.004

Canadian Journal of Ophthalmology

2020

DOI: 10.1016/j.jcjo.2019.08.004

|View full text |Cite

Effect of 6-week washout period on intraocular pressure following chronic prostaglandin analogue treatment: a randomized controlled trial

Carter W. Lim

Vlad Diaconita

Eddie Liu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5À8 In this issue, Lim et al investigated whether the IOP-lowering effects of chronic PGA use persist after discontinuation. 9 Eighty-seven patients (154 eyes) with OAG or OAG suspects on monotherapy PGA for 6 months who achieved 20% IOP reduction from baseline were enrolled in this prospective, single-blinded, parallel, single-centre, randomized controlled clinical trial. Of these, 48 participants (85 eyes) were randomized to the "washout" group, which discontinued PGA therapy, and 39 participants (69 eyes) were randomized to the control group, which continued PGA therapy.…”

mentioning

confidence: 99%

Resident Perspectives 55–2

Qian¹,

Sundaram²,

Donaldson³

et al. 2020

Canadian Journal of Ophthalmology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Resident Perspectives 55–2

Qian¹,

Sundaram²,

Donaldson³

et al. 2020

Canadian Journal of Ophthalmology

View full text Add to dashboard Cite

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review

Benitez,

Anter,

Arcuri

et al. 2024

Current Opinion in Pharmacology

View full text Add to dashboard Cite

From Eye Care to Hair Growth: Bimatoprost

Zeppieri,

Gagliano,

Spadea

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Background: Bimatoprost has emerged as a significant medication in the field of medicine over the past several decades, with diverse applications in ophthalmology, dermatology, and beyond. Originally developed as an ocular hypotensive agent, it has proven highly effective in treating glaucoma and ocular hypertension. Its ability to reduce intraocular pressure has established it as a first-line treatment option, improving management and preventing vision loss. In dermatology, bimatoprost has shown promising results in the promotion of hair growth, particularly in the treatment of alopecia and hypotrichosis. Its mechanism of action, stimulating the hair cycle and prolonging the growth phase, has led to the development of bimatoprost-containing solutions for enhancing eyelash growth. Aim: The aim of our review is to provide a brief description, overview, and studies in the current literature regarding the versatile clinical use of bimatoprost in recent years. This can help clinicians determine the most suitable individualized therapy to meet the needs of each patient. Methods: Our methods involve a comprehensive review of the latest advancements reported in the literature in bimatoprost formulations, which range from traditional eye drops to sustained-release implants. These innovations offer extended drug delivery, enhance patient compliance, and minimize side effects. Results: The vast literature published on PubMed has confirmed the clinical usefulness of bimatoprost in lowering intraocular pressure and in managing patients with glaucoma. Numerous studies have shown promising results in dermatology and esthetics in promoting hair growth, particularly in treating alopecia and hypotrichosis. Its mechanism of action involves stimulating the hair cycle and prolonging the growth phase, leading to the development of solutions that enhance eyelash growth. The global use of bimatoprost has expanded significantly, with applications growing beyond its initial indications. Ongoing research is exploring its potential in glaucoma surgery, neuroprotection, and cosmetic procedures. Conclusions: Bimatoprost has shown immense potential for addressing a wide range of therapeutic needs through various formulations and advancements. Promising future perspectives include the exploration of novel delivery systems such as contact lenses and microneedles to further enhance drug efficacy and patient comfort. Ongoing research and future perspectives continue to shape its role in medicine, promising further advancements and improved patient outcomes.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Effect of 6-week washout period on intraocular pressure following chronic prostaglandin analogue treatment: a randomized controlled trial

Cited by 3 publications

References 33 publications

Resident Perspectives 55–2

Resident Perspectives 55–2

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review

From Eye Care to Hair Growth: Bimatoprost

Contact Info

Product

Resources

About